Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 587-605 , December 2007

New hepatic targets for glycaemic control in diabetes

Dedication: I would like to dedicate this chapter to George Alberti in celebration of his 70th birthday.

  • Loranne Agius, BSc, DPhil, DSc (Professor)

      Affiliations

    • Corresponding Author InformationTel.: +44 1912227033; Fax: +44 1912220723.

References 

  1. DeFronzo RA, Ferrannini E, Hendler R, et al. Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. Proceedings of the National Academy of Sciences of the United States of America. 1978;75:5173–5177
  2. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999;48:1198–1214
  3. Bollen M, Keppens S, Stalmans W. Specific features of glycogen metabolism in the liver. Biochemical Journal. 1998;336:19–31
  4. Agius L. The physiological role of glucokinase binding and translocation in hepatocytes. Advances In Enzyme Regulation. 1998;38:303–331
  5. Agius L, Aiston S, Mukhtar M, et al. GKRP/GK Control of metabolic fluxes in hepatocytes. In: Glucokinase and Glycaemic disease. Frontiers in Diabetes. 16:2004;p. 208–221
  6. Mevorach M, Giacca A, Aharon Y, et al. Regulation of endogenous glucose production by glucose per se is impaired in type-2 diabetes mellitus. The Journal of Clinical Investigation. 1998;102:744–753
  7. Basu R, Basu A, Johnson CM, et al. Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type-2 diabetes. Diabetes. 2004;53:2042–2050
  8. Brichard SM, Henquin JC, Girard J. Phlorizin treatment of diabetic rats partially reverses the abnormal expression of genes involved in hepatic glucose metabolism. Diabetologia. 1993;36:292–298
  9. Massillon D, Barzilai N, Chen W, et al. Glucose regulates in vivo glucose-6-phosphatase gene expression in the liver of diabetic rats. The Journal of Biological Chemistry. 1996;271:9871–9874
  10. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type-2 diabetes and therapeutic implications. Endocrine Reviews. 2007;28:253–283
  11. Payne VA, Arden C, Wu C, et al. Dual role of phosphofructokinase-2/fructose bisphosphatase-2 in regulating the compartmentation and expression of glucokinase in hepatocytes. Diabetes. 2005;54:1949–1957
  12. Sorensen H, Brand CL, Neschen S, et al. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes. 2006;55:2843–2848
  13. Parker JC, Andrews KM, Allen MR, et al. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochemical and Biophysical Research. 2002;290:839–843
  14. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:1438–1443
  15. Liang Y, Osborne MC, Monia BP, et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes. 2004;53:410–417
  16. Qureshi SA, Rios Candelore M, Xie D, et al. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes. 2004;53:3267–3273
  17. Rivera N, Everett-Grueter CA, Edgerton DS, et al. A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. The Journal of Pharmacology and Experimental Therapeutics. 2007;321:743–752
  18. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 2001;44:2018–2024
  19. Claus TH, Pan CQ, Buxton JM, et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type-2 diabetes. The Journal of Endocrinology. 2007;192:371–380
  20. Parker JC, McPherson RK, Andrews KM, et al. Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes. 2000;49:2079–2086
  21. McCormack JG, Westergaard N, Kristiansen M, et al. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Current Pharmaceutical Design. 2001;7:1451–1474
  22. Westergaard N, Madsen P, Lundbeck JM, et al. Identification of two novel and potent competitive inhibitors of the glucose-6-phosphatase catalytic protein. Diabetes, Obesity & Metabolism. 2002;4:96–105
  23. Clore JN, Stillman J, Sugerman H. Glucose-6-phosphatase flux in vitro is increased in type-2 diabetes. Diabetes. 2000;49:969–974
  24. Trinh KY, O'Doherty RM, Anderson P, et al. Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. The Journal of Biological Chemistry. 1998;273:31615–31620
  25. Westergaard N, Brand CL, Lewinsky RH, et al. Peroxyvanadium compounds inhibit glucose-6-phosphatase activity and glucagon-stimulated hepatic glucose output in the rat in vivo. Archives of Biochemistry and Biophysics. 1999;366:55–60
  26. Parker JC, VanVolkenburg MA, Levy CB, et al. Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocator. Diabetes. 1998;47:1630–1636
  27. Aiston S, Trinh KY, Lange AJ, et al. Glucose-6-phosphatase overexpression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation. Evidence against feedback inhibition of glucokinase. The Journal of Biological Chemistry. 1999;274:24559–24566
  28. van Dijk TH, van der Sluijs FH, Wiegman CH, et al. Acute inhibition of hepatic glucose-6-phosphatase does not affect gluconeogenesis but directs gluconeogenic flux toward glycogen in fasted rats. A pharmacological study with the chlorogenic acid derivative S4048. The Journal of Biological Chemistry. 2001;276:25727–25735
  29. Bandsma RH, Wiegman CH, Herling AW, et al. Acute inhibition of glucose-6-phosphate translocator activity leads to increased de novo lipogenesis and development of hepatic steatosis without affecting VLDL production in rats. Diabetes. 2001;50:2591–2597
  30. Harndahl L, Schmoll D, Herling AW, et al. The role of glucose 6-phosphate in mediating the effects of glucokinase overexpression on hepatic glucose metabolism. The FEBS Journal. 2006;273:336–346
  31. Herling AW, Burger H, Schubert G, et al. Alterations of carbohydrate and lipid intermediary metabolism during inhibition of glucose-6-phosphatase in rats. European Journal of Pharmacology. 1999;386:75–82
  32. Foufelle F, Girard J, Ferre P. Glucose regulation of gene expression. Current Opinion in Clinical Nutrition and Metabolic Care. 1998;1:323–328
  33. Wajngot A, Chandramouli V, Schumann WC, et al. Quantitative contributions of gluconeogenesis to glucose production during fasting in type-2 diabetes mellitus. Metabolism. 2001;50:47–52
  34. Vincent MF, Erion MD, Gruber HE, et al. Hypoglycaemic effect of AICAriboside in mice. Diabetologia. 1996;39:1148–1155
  35. Erion MD, van Poelje PD, Dang Q, et al. MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type-2 diabetes. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:7970–7975
  36. van Poelje PD, Potter SC, Chandramouli VC, et al. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. Diabetes. 2006;55:1747–1754
  37. Wright SW, Carlo AA, Danley DE, et al. 3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site. Bioorganic & Medicinal Chemistry Letters. 2003;13:2055–2058
  38. Wright SW, Carlo AA, Carty MD, et al. Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography. Journal of Medicinal Chemistry. 2002;45:3865–3877
  39. Choe JY, Nelson SW, Arienti KL, et al. Inhibition of fructose-1,6-bisphosphatase by a new class of allosteric effectors. The Journal of Biological Chemistry. 2003;278:51176–51183
  40. Edgerton DS, Cardin S, Emshwiller M, et al. Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes. 2001;50:1872–1882
  41. Aiston S, Coghlan MP, Agius L. Inactivation of phosphorylase is a major component of the mechanism by which insulin stimulates hepatic glycogen synthesis. European Journal of Biochemistry. 2003;270:2773–2781
  42. Roesler WJ, Khandelwal RL. Quantitation of glycogen synthase and phosphorylase protein in mouse liver: correlation between enzymatic protein and enzyme activity. Archives of Biochemistry and Biophysics. 1986;244:397–407
  43. Aiston S, Peak M, Agius L. Impaired glycogen synthesis in hepatocytes from Zucker fatty fa/fa rats: the role of increased phosphorylase activity. Diabetologia. 2000;43:589–597
  44. Treadway JL, Mendys P, Hoover DJ. Glycogen phosphorylase inhibitors for treatment of type-2 diabetes mellitus. Expert Opinion on Investigational Drugs. 2001;10:439–454
  45. Henke BR & Sparks SM. Glycogen phosphorylase inhibitors. 2006; 6: 845–857.
  46. Newgard CB, Hwang PK, Fletterick RJ. The family of glycogen phosphorylases: structure and function. Critical Reviews In Biochemistry and Molecular Biology. 1989;24:69–99
  47. Oikonomakos NG. Glycogen phosphorylase as a molecular target for type-2 diabetes therapy. Current Protein & Peptide Science. 2002;3:561–586
  48. Aiston S, Green A, Mukhtar M, et al. Glucose 6-phosphate causes translocation of phosphorylase in hepatocytes and inactivates the enzyme synergistically with glucose. Biochemical Journal. 2004;377:195–204
  49. Ferris SA. Hepatic glucokinase activity in human diabetics and nondiabetics. Metabolism. 1964;13:1478–1481
  50. Caro JF, Triester S, Patel VK, et al. Liver glucokinase: decreased activity in patients with type II diabetes. Hormone and Metabolic Research. 1995;27:19–22
  51. Board M, Bollen M, Stalmans W, et al. Effects of C-1-substituted glucose analogue on the activation states of glycogen synthase and glycogen phosphorylase in rat hepatocytes. Biochemical Journal. 1995;311:845–852
  52. Board M, Hadwen M, Johnson LN. Effects of novel analogues of D-glucose on glycogen phosphorylase activities in crude extracts of liver and skeletal muscle. European Journal of Biochemistry. 1995;228:753–761
  53. Andersen B, Westergaard N. The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors. Biochemical Journal. 2002;367:443–450
  54. Andersen B, Rassov A, Westergaard N, et al. Inhibition of glycogenolysis in primary rat hepatocytes by 1, 4-dideoxy-1,4-imino-D-arabinitol. Biochemical Journal. 1999;342:545–550
  55. Jakobsen P, Lundbeck JM, Kristiansen M, et al. Iminosugars: potential inhibitors of liver glycogen phosphorylase. Bioorganic & Medicinal Chemistry. 2001;9:733–744
  56. Fosgerau K, Westergaard N, Quistorff B, et al. Kinetic and functional characterization of 1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice. Archives of Biochemistry and Biophysics. 2000;380:274–284
  57. Fosgerau K, Breinholt J, McCormack JG, et al. Evidence against glycogen cycling of gluconeogenic substrates in various liver preparations. The Journal of Biological Chemistry. 2002;277:28648–28655
  58. Oikonomakos NG, Tiraidis C, Leonidas DD, et al. Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition. Journal of Medicinal Chemistry. 2006;49:5687–5701
  59. Latsis T, Andersen B, Agius L. Diverse effects of two allosteric inhibitors on the phosphorylation state of glycogen phosphorylase in hepatocytes. Biochemical Journal. 2002;368:309–316
  60. Bergans N, Stalmans W, Goldmann S, et al. Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401: inhibition and inactivation of glycogen phosphorylase by an activated metabolite. Diabetes. 2000;49:1419–1426
  61. Oikonomakos NG, Tsitsanou KE, Zographos SE, et al. Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarbo xylate. Protein Science. 1999;8:1930–1945
  62. Shiota M, Jackson PA, Bischoff H, et al. Inhibition of glycogenolysis enhances gluconeogenic precursor uptake by the liver of conscious dogs. American Journal of Physiology. 1997;273:E868–E879
  63. Kristiansen M, Andersen B, Iversen LF, et al. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site. Journal of Medicinal Chemistry. 2004;47:3537–3545
  64. Lu Z, Bohn J, Bergeron R, et al. A new class of glycogen phosphorylase inhibitors. Bioorganic & Medicinal Chemistry Letters. 2003;13:4125–4128
  65. Ogawa AK, Willoughby CA, Bergeron R, et al. Glucose-lowering in a db/db mouse model by dihydropyridine diacid glycogen phosphorylase inhibitors. Bioorganic & Medicinal Chemistry Letters. 2003;13:3405–3408
  66. Klabunde T, Wendt KU, Kadereit D, et al. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type-2 diabetes. Journal of Medicinal Chemistry. 2005;48:6178–6193
  67. Oikonomakos NG, Kosmopoulou MN, Chrysina ED, et al. Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs. Protein Science. 2005;14:1760–1771
  68. Baker DJ, Greenhaff PL, MacInnes A, et al. The experimental type-2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction. Diabetes. 2006;55:1855–1861
  69. Wen X, Sun H, Liu J, et al. Pentacyclic triterpenes. Part 1: the first examples of naturally occurring pentacyclic triterpenes as a new class of inhibitors of glycogen phosphorylases. Bioorganic & Medicinal Chemistry Letters. 2005;15:4944–4948
  70. Furukawa S, Tsurumi Y, Murakami K, et al. FR258900, a novel glycogen phosphorylase inhibitor isolated from Fungus No. 138354. I. Taxonomy, fermentation, isolation and biological activities. The Journal of Antibiotics. 2005;58:497–502
  71. Furukawa S, Murakami K, Nishikawa M, et al. FR258900, a novel glycogen phosphorylase inhibitor isolated from Fungus No. 138354. II. Anti-hyperglycemic effects in diabetic animal models. The Journal of Antibiotics. 2005;58:503–506
  72. Tiraidis C, Alexacou KM, Zographos SE, et al. FR258900, a potential anti-hyperglycemic drug, binds at the allosteric site of glycogen phosphorylase. Protein Science. 2007;16:1773–1782
  73. Martin WH, Hoover DJ, Armento SJ, et al. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:1776–1781
  74. Hoover DJ, Lefkowitz-Snow S, Burgess-Henry JL, et al. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. Journal of Medicinal Chemistry. 1998;41:2934–2938
  75. Rath VL, Ammirati M, LeMotte PK, et al. Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core. Molecular Cell. 2000;6:139–148
  76. Oikonomakos NG, Skamnaki VT, Tsitsanou KE, et al. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure. 2000;8:575–584
  77. Rath VL, Ammirati M, Danley DE, et al. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chemistry & Biology. 2000;7:677–682
  78. Aiston S, Hampson L, Gomez-Foix AM, et al. Hepatic glycogen synthesis is highly sensitive to phosphorylase activity: evidence from metabolic control analysis. The Journal of Biological Chemistry. 2001;276:23858–23866
  79. Hampson LJ, Agius L. Increased potency and efficacy of combined phosphorylase inactivation and glucokinase activation in control of hepatocyte glycogen metabolism. Diabetes. 2005;54:617–623
  80. Rosauer KG, Ogawa AK, Willoughby CA, et al. Novel 3,4-dihydroquinolin-2(1H)-one inhibitors of human glycogen phosphorylase a. Bioorganic & Medicinal Chemistry Letters. 2003;13:4385–4388
  81. Whittamore PR, Addie MS, Bennett SN, et al. Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies. Bioorganic & Medicinal Chemistry Letters. 2006;16:5567–5571
  82. Birch AM, Kenny PW, Oikonomakos NG, et al. Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors. Bioorganic & Medicinal Chemistry Letters. 2007;17:394–399
  83. Freeman S, Bartlett JB, Convey G, et al. Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. British Journal of Pharmacology. 2006;149:775–785
  84. Ekstrom JL, Pauly TA, Carty MD, et al. Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase. Chemistry & Biology. 2002;9:915–924
  85. Kaiser A, Nishi K, Gorin FA, et al. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Archives of Biochemistry and Biophysics. 2001;386:179–187
  86. Oikonomakos NG, Schnier JB, Zographos SE, et al. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. The Journal of Biological Chemistry. 2000;275:34566–34573
  87. Hampson LJ, Arden C, Agius L, et al. Bioactivity of glycogen phosphorylase inhibitors that bind to the purine nucleoside site. Bioorganic & Medicinal Chemistry. 2006;14:7835–7845
  88. Jakobs S, Fridrich D, Hofem S, et al. Natural flavonoids are potent inhibitors of glycogen phosphorylase. Molecular Nutrition & Food Research. 2006;50:52–57
  89. Treadway JL. Symposia on New targets for Glycaemic Control, 65th American Diabetes Association National Meeting, San Diego, California. 2005.
  90. Matschinsky FM, Magnuson MA, Zelent D, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes. 2006;55:1–12
  91. Zelent D, Najafi H, Odili S, et al. Glucokinase and glucose homeostasis: proven concepts and new ideas. Biochemical Society Transactions. 2005;33:306–310
  92. Agius L, Peak M, Newgard CB, et al. Evidence for a role of glucose-induced translocation of glucokinase in the control of hepatic glycogen synthesis. The Journal of Biological Chemistry. 1996;271:30479–30486
  93. Willms B, Ben-Ami- P, Soling HD. Hepatic enzyme activities of glycolysis and gluconeogenesis in diabetes of man and laboratory animals. Hormone and Metabolic Research. 1970;2:135–141
  94. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003;301:370–373
  95. Brocklehurst KJ, Payne VA, Davies RA, et al. Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes. 2004;53:535–541
  96. Kamata K, Mitsuya M, Nishimura T, et al. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure. 2004;12:429–438
  97. Grimsby J, Matschinsky FM, Grippo EJ. Discovery and actions of Glucokinase activators. In: Glucokinase and Glycaemic disease. Frontiers in Diabetes. 16:2004;p. 360–378
  98. McKerrecher D, Allen JV, Bowker SS, et al. Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorganic & Medicinal Chemistry Letters. 2005;15:2103–2106
  99. Coope GJ, Atkinson AM, Allott C, et al. Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats. British Journal of Pharmacology. 2006;149:328–335
  100. Futamura M, Hosaka H, Kadotani A, et al. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. The Journal of Biological Chemistry. 2006;281:37668–37674
  101. Efanov AM, Barrett DG, Brenner MB, et al. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology. 2005;146:3696–3701
  102. Castelhano AL, Dong H, Fyfe MC, et al. Glucokinase-activating ureas. Bioorganic & Medicinal Chemistry Letters. 2005;15:1501–1504
  103. Fyfe MC, White JR, Taylor A, et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia. 2007;50:1277–1287
  104. Guertin KR, Grimsby J. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Current Medicinal Chemistry. 2006;13:1839–1843
  105. O'Doherty RM, Lehman DL, Telemaque-Potts S, et al. Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes. 1999;48:2022–2027
  106. Ferre T, Riu E, Franckhauser S, et al. Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia. 2003;46:1662–1668
  107. Hariharan N, Farrelly D, Hagan D, et al. Expression of human hepatic glucokinase in transgenic mice liver results in decreased glucose levels and reduced body weight. Diabetes. 1997;46:11–16

PII: S1521-690X(07)00084-X

doi: 10.1016/j.beem.2007.09.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 587-605 , December 2007

Article Tools

* Image Usage & Resolution